Celcuity’s (CELC) “Buy” Rating Reiterated at HC Wainwright

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $27.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 48.68% from the stock’s previous close.

Separately, Stifel Nicolaus assumed coverage on Celcuity in a research report on Thursday, February 22nd. They issued a “buy” rating and a $40.00 target price on the stock.

Celcuity Price Performance

NASDAQ:CELC opened at $18.16 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 11.15 and a current ratio of 11.15. The stock’s 50-day simple moving average is $16.20 and its 200 day simple moving average is $13.51. The company has a market cap of $439.47 million, a P/E ratio of -6.65 and a beta of 0.74. Celcuity has a 52-week low of $8.39 and a 52-week high of $18.95.

Hedge Funds Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently bought and sold shares of CELC. Perceptive Advisors LLC bought a new position in Celcuity during the fourth quarter worth about $21,583,000. BlackRock Inc. boosted its holdings in shares of Celcuity by 599.7% during the second quarter. BlackRock Inc. now owns 912,972 shares of the company’s stock worth $10,024,000 after acquiring an additional 782,486 shares during the period. Soleus Capital Management L.P. boosted its holdings in shares of Celcuity by 172.6% during the fourth quarter. Soleus Capital Management L.P. now owns 1,210,228 shares of the company’s stock worth $16,955,000 after acquiring an additional 766,316 shares during the period. Captrust Financial Advisors boosted its holdings in shares of Celcuity by 12,563.8% during the third quarter. Captrust Financial Advisors now owns 633,189 shares of the company’s stock worth $6,357,000 after acquiring an additional 628,189 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of Celcuity by 23.5% during the third quarter. Morgan Stanley now owns 1,967,776 shares of the company’s stock worth $17,985,000 after acquiring an additional 374,196 shares during the period. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.